Dr. Grosu founded PetDx in 2019 after his beloved dog Poppy succumbed to pancreatic cancer at the age of 4, less than two months after her diagnosis. The ordeal motivated him to assemble a team of experts in genomics and veterinary medicine around a simple goal: using the latest advances in genome sequencing to revolutionize the early detection of cancer in pets.
Most recently, Grosu, who studied medicine at Saint Louis University School of Medicine and earned an MBA from the University of Oxford, served as chief medical officer at Sequenom. Previously, he had been the first chief medical officer of Illumina, where he established the clinical development and medical affairs operations, and led the clinical studies underlying regulatory clearance of the world’s first next-generation sequencing IVD platform and assay. While at Illumina, he also directed the clinical studies in support of a companion diagnostic co-developed with Amgen that resulted in premarket approval of the Praxis Extended RAS Panel, the first next-generation sequencing-based oncology IVD.
Earlier in his career, Grosu held positions of increasing responsibility in medical affairs and clinical development at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson, where he focused on diagnostic applications in oncology. In addition to his role as PetDx’s President and CEO, Grosu is the chairman of its Board of Directors. Outside of PetDx, he is an active biotechnology investor and an accomplished scuba diver who has explored marine environments around the world.